EU/3/13/1212

About

On 16 January 2014, orphan designation (EU/3/13/1212) was granted by the European Commission to Janssen-Cilag International N.V., Belgium, for ibrutinib for the treatment of follicular lymphoma.

Key facts

Active substance
Ibrutinib
Disease / condition
Treatment of follicular lymphoma
Date of first decision
16/01/2014
Outcome
Positive
EU designation number
EU/3/13/1212

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Janssen-Cilag International N.V.
Turnhoutseweg, 30
2340 Beerse
Belgium
Tel. +32 146 031 89
Fax +32 146 055 33
E-mail: http://www.janssen-emea.com/contactus

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating